U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C72H112O48S8
Molecular Weight 2002.151
Optical Activity UNSPECIFIED
Defined Stereocenters 40 / 40
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SUGAMMADEX

SMILES

[H][C@@]12O[C@H](CSCCC(O)=O)[C@@H](O[C@@]3([H])O[C@H](CSCCC(O)=O)[C@@H](O[C@@]4([H])O[C@H](CSCCC(O)=O)[C@@H](O[C@@]5([H])O[C@H](CSCCC(O)=O)[C@@H](O[C@@]6([H])O[C@H](CSCCC(O)=O)[C@@]([H])(O[C@H]7O[C@H](CSCCC(O)=O)[C@@]([H])(O[C@H]8O[C@H](CSCCC(O)=O)[C@@]([H])(O[C@H]9O[C@H](CSCCC(O)=O)[C@@H](O1)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O

InChI

InChIKey=WHRODDIHRRDWEW-VTHZAVIASA-N
InChI=1S/C72H112O48S8/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88)/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-/m1/s1

HIDE SMILES / InChI
Molecular Formula C72H112O48S8
Molecular Weight 2002.151
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 40 / 40
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022225lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/25885973

Sugammadex (ORG 25969) is a cyclodextrin derivative was synthesized as synthetic receptor (or host molecule) for neuromuscular blockers (rocuronium and vecuronium). It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium and vecuronium. The clinical use of sugammadex promises to eliminate many of the shortcomings in current anesthetic practice with regard to antagonism of rocuronium and other aminosteroid muscle relaxants. Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.

CNS Activity

CNS Active
3913
Curator's Comment: Sugammadex passes across blood brain barrier in a very low ratio (< 3% in rats) and intracerebroventricular Sugammadex administration did not result in any changes in behavioral status, locomotor activity or posture in animals. However sugammadex had a neuroprotective effect in a transient global cerebral ischemia/reperfusion rat model.

Originator

Approval Year

2015
471
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1064
CHEMBL1201219: VECURONIUM
2
Target ID: CHEMBL1201219: VECURONIUM
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8429
BRIDION

Approved Use

BRIDION (sugammadex) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery

Launch Date

2015
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
66.1 ug/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02011490
4 mg/kg single, intravenous bolus
dose: 4 mg/kg
route of administration: intravenous bolus
experiment type: single
co-administered:
SUGAMMADEX plasma
Homo sapiens
population: healthy
age:
sex:
food status:
60.6 ug/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02011490
4 mg/kg single, intravenous bolus
dose: 4 mg/kg
route of administration: intravenous bolus
experiment type: single
co-administered:
SUGAMMADEX plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
62.2 ug/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02011490
4 mg/kg single, intravenous bolus
dose: 4 mg/kg
route of administration: intravenous bolus
experiment type: single
co-administered:
SUGAMMADEX plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
61.1 ug*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02011490
4 mg/kg single, intravenous bolus
dose: 4 mg/kg
route of administration: intravenous bolus
experiment type: single
co-administered:
SUGAMMADEX plasma
Homo sapiens
population: healthy
age:
sex:
food status:
148 ug*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02011490
4 mg/kg single, intravenous bolus
dose: 4 mg/kg
route of administration: intravenous bolus
experiment type: single
co-administered:
SUGAMMADEX plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
335 ug*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02011490
4 mg/kg single, intravenous bolus
dose: 4 mg/kg
route of administration: intravenous bolus
experiment type: single
co-administered:
SUGAMMADEX plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
Doses

Doses

DosePopulationAdverse events​
96 mg/kg single, intravenous
Highest studied dose
Dose: 96 mg/kg
Route: intravenous
Route: single
Dose: 96 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
healthy, 18-65 years
n = 12
Health Status: healthy
Age Group: 18-65 years
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
Other AEs: Dysgeusia, Headache...
Other AEs:
Dysgeusia (66.7%)
Headache (16.7%)
Fatigue (16.7%)
Nausea (16.7%)
Dizziness postural (8.3%)
Abdominal pain (8.3%)
Pharyngolaryngeal pain (16.7%)
Micturition urgency (8.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
16 mg/kg single, intravenous
Recommended
Dose: 16 mg/kg
Route: intravenous
Route: single
Dose: 16 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
unhealthy
n = 496
Health Status: unhealthy
Population Size: 496
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
Disc. AE: Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Anaphylactic shock (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
4 mg/kg single, intravenous
Recommended
Dose: 4 mg/kg
Route: intravenous
Route: single
Dose: 4 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
unhealthy
n = 1505
Health Status: unhealthy
Population Size: 1505
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
Disc. AE: Hypersensitivity reaction...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity reaction (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
32 mg/kg single, intravenous
Dose: 32 mg/kg
Route: intravenous
Route: single
Dose: 32 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
unhealthy
n = 165
Health Status: unhealthy
Population Size: 165
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
Disc. AE: Hypersensitivity reaction...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity reaction (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
8 mg/kg single, intravenous
Dose: 8 mg/kg
Route: intravenous
Route: single
Dose: 8 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
unhealthy
n = 156
Health Status: unhealthy
Population Size: 156
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
Disc. AE: Tachycardia...
AEs leading to
discontinuation/dose reduction:
Tachycardia (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
AEs

AEs

AESignificanceDosePopulation
Fatigue 16.7%
96 mg/kg single, intravenous
Highest studied dose
Dose: 96 mg/kg
Route: intravenous
Route: single
Dose: 96 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
healthy, 18-65 years
n = 12
Health Status: healthy
Age Group: 18-65 years
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
Headache 16.7%
96 mg/kg single, intravenous
Highest studied dose
Dose: 96 mg/kg
Route: intravenous
Route: single
Dose: 96 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
healthy, 18-65 years
n = 12
Health Status: healthy
Age Group: 18-65 years
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
Nausea 16.7%
96 mg/kg single, intravenous
Highest studied dose
Dose: 96 mg/kg
Route: intravenous
Route: single
Dose: 96 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
healthy, 18-65 years
n = 12
Health Status: healthy
Age Group: 18-65 years
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
Pharyngolaryngeal pain 16.7%
96 mg/kg single, intravenous
Highest studied dose
Dose: 96 mg/kg
Route: intravenous
Route: single
Dose: 96 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
healthy, 18-65 years
n = 12
Health Status: healthy
Age Group: 18-65 years
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
Dysgeusia 66.7%
96 mg/kg single, intravenous
Highest studied dose
Dose: 96 mg/kg
Route: intravenous
Route: single
Dose: 96 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
healthy, 18-65 years
n = 12
Health Status: healthy
Age Group: 18-65 years
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
Abdominal pain 8.3%
96 mg/kg single, intravenous
Highest studied dose
Dose: 96 mg/kg
Route: intravenous
Route: single
Dose: 96 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
healthy, 18-65 years
n = 12
Health Status: healthy
Age Group: 18-65 years
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
Dizziness postural 8.3%
96 mg/kg single, intravenous
Highest studied dose
Dose: 96 mg/kg
Route: intravenous
Route: single
Dose: 96 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
healthy, 18-65 years
n = 12
Health Status: healthy
Age Group: 18-65 years
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
Micturition urgency 8.3%
96 mg/kg single, intravenous
Highest studied dose
Dose: 96 mg/kg
Route: intravenous
Route: single
Dose: 96 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
healthy, 18-65 years
n = 12
Health Status: healthy
Age Group: 18-65 years
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/20825252
Anaphylactic shock 1 patient
Disc. AE
16 mg/kg single, intravenous
Recommended
Dose: 16 mg/kg
Route: intravenous
Route: single
Dose: 16 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
unhealthy
n = 496
Health Status: unhealthy
Population Size: 496
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
Hypersensitivity reaction 1 patient
Disc. AE
4 mg/kg single, intravenous
Recommended
Dose: 4 mg/kg
Route: intravenous
Route: single
Dose: 4 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
unhealthy
n = 1505
Health Status: unhealthy
Population Size: 1505
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
Hypersensitivity reaction 1 patient
Disc. AE
32 mg/kg single, intravenous
Dose: 32 mg/kg
Route: intravenous
Route: single
Dose: 32 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
unhealthy
n = 165
Health Status: unhealthy
Population Size: 165
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
Tachycardia 1 patient
Disc. AE
8 mg/kg single, intravenous
Dose: 8 mg/kg
Route: intravenous
Route: single
Dose: 8 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
unhealthy
n = 156
Health Status: unhealthy
Population Size: 156
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf
Page: p. 66
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:90953
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:90953
ChemicalBook
CB71011756
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB71011756
MolPort
MolPort-046-424-800
https://www.molport.com/shop/molecule-link/MolPort-046-424-800
PubMed

PubMed

TitleDatePubMed
Patents

Patents

WO2016194001A1
2

Sample Use Guides

In Vivo Use Guide
BRIDION (sugammadex) can be used to reverse different levels of rocuronium- or vecuronium-induced neuromuscular blockade. For rocuronium and vecuronium: • A dose of 4 mg/kg BRIDION is recommended if spontaneous recovery of the twitch response has reached 1 to 2 post-tetanic counts (PTC) and there are no twitch responses to train-of-four (TOF) stimulation following rocuronium- or vecuronium-induced neuromuscular blockade. • A dose of 2 mg/kg BRIDION is recommended if spontaneous recovery has reached the reappearance of the second twitch (T2) in response to TOF stimulation following rocuronium- or vecuronium-induced neuromuscular blockade. For rocuronium only: • A dose of 16 mg/kg BRIDION is recommended if there is a clinical need to reverse neuromuscular blockade soon (approximately 3 minutes) after administration of a single dose of 1.2 mg/kg of rocuronium. The efficacy of the 16 mg/kg dose of BRIDION following administration of vecuronium has not been studied.
Route of Administration: Intravenous
In Vitro Use Guide
75 ug/ml sugammadex causes apoptotic/necrosis neuron death in primary cultures.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:32:00 GMT 2023
Edited
by admin
on Fri Dec 15 16:32:00 GMT 2023
Record UNII
361LPM2T56
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SUGAMMADEX
EMA EPAR   INN   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-
Common Name English
Sugammadex [WHO-DD]
Common Name English
6,6',6'',6''',6'''',6''''',6'''''',6'''''''-OCTAKIS-S-(2-CARBOXYLATOETHYL)-6,6',6'',6''',6'''',6''''',6'''''',6'''''''-OCTATHIOCYCLO-.ALPHA.-(1->4)-D-OCTAGLUCOPYRANOSIDE
Common Name English
SUGAMMADEX [USAN]
Common Name English
SUGAMMADEX [EMA EPAR]
Common Name English
SUGAMMADEX [MI]
Common Name English
sugammadex [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QV03AB35
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
WHO-ATC V03AB35
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
NCI_THESAURUS C26170
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C80629
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
RXCUI
1726988
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY RxNorm
CAS
343306-71-8
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
PUBCHEM
6918585
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
WIKIPEDIA
SUGAMMADEX
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
NDF-RT
N0000168522
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY gamma-Cyclodextrins [Chemical/Ingredient]
FDA UNII
361LPM2T56
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
EVMPD
SUB26695
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
MESH
C453980
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
DRUG CENTRAL
4233
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
MERCK INDEX
m10289
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID90895043
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
DRUG BANK
DB06206
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
INN
8528
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
SMS_ID
100000089639
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
CHEBI
90953
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
ChEMBL
CHEMBL2111107
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
USAN
CD-10
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
LACTMED
Sugammadex
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
DAILYMED
361LPM2T56
Created by admin on Fri Dec 15 16:32:00 GMT 2023 , Edited by admin on Fri Dec 15 16:32:00 GMT 2023
PRIMARY
Related Record Type Details
Structure of VECURONIUM
LIGAND->BINDER
Structure of SUGAMMADEX
EXCRETED UNCHANGED
On an average, more than 90% of sugammadex was recovered in urine within 24 hours. Other PK studies also showed that 65-97% of the dose was recovered in urine. The differences in urine excretion percentage may be partly due to error associated with urine sample collection.
URINE
Structure of ROCURONIUM
LIGAND->BINDER
Structure of SUGAMMADEX SODIUM
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of SUGAMMADEX
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966